Adopting a quality philosophy that goes beyond mere regulatory compliance is essential to standing out in the pharmaceutical industry. The integration of advanced technologies, such as biometrics, represents an effective solution to ensure regulatory compliance and achieve superior quality standards.

Ensuring the integrity of data collected in clinical trials is essential and represents a critical step in the introduction of new drugs to the market. The implementation of biometric electronic signatures in Electronic Data Capture (EDCs) ensures their accuracy and reliability.

The biometric electronic signature within the audit trail action log ensures the integrity of records in GMP regulated environments, providing detailed and reliable tracking of recorded activities.

The pharmaceutical industry must ensure compliance with GMP regulations, which include a number of issues, including data integrity. The adoption of biometric technologies, such as iris or fingerprint recognition, emerges as the solution to ensure compliance.

Within GxP regulated environments, it is essential to ensure data integrity and traceability of actions throughout the supply chain. The adoption of biometric technologies, such as iris or fingerprint recognition, emerges as the solution to ensure compliance.

Non-compliance with GMP regulations, particularly in critical factors such as data integrity and employee identification in manufacturing tasks, can lead to regulatory agencies issuing warning letters and even suspending manufacturing operations. How do you effectively address and prevent these consequences to ensure compliance?

The FDA and EMA share the goal of ensuring compliance with GMP and other applicable regulations in pharmaceutical manufacturing. These entities carry out exhaustive inspections of companies to verify their compliance with established standards. Is your company ready to face the rigorous inspection processes?

RFID cards provide some advantages when used for access control and as an electronic signature for employees in pharmaceutical production processes. However, they present a series of inconveniences that make the regulations themselves not accept them as the exclusive method of identification.